These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8137342

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Pharmacokinetics and metabolism of anthracyclines in man].
    Robert J.
    Pathol Biol (Paris); 1987 Jan; 35(1):27-30. PubMed ID: 3550609
    [Abstract] [Full Text] [Related]

  • 5. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
    Hurteloup P, Ganzina F.
    Drugs Exp Clin Res; 1986 Jan; 12(1-3):233-46. PubMed ID: 3525075
    [Abstract] [Full Text] [Related]

  • 6. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN.
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Idarubicin: a brief overview on pharmacology and clinical use.
    Borchmann P, Hübel K, Schnell R, Engert A.
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):80-3. PubMed ID: 9147715
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
    Morgan DJ, Hill JS, Clarke K, Stylli SS, Park SJ, Cebon J, Basser RL, Kaye AH, Geldard H, Maher DW, Green MD.
    Cancer Chemother Pharmacol; 1997 Feb; 40(3):202-8. PubMed ID: 9219502
    [Abstract] [Full Text] [Related]

  • 11. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R.
    Anticancer Res; 2000 Feb; 20(1B):485-91. PubMed ID: 10769710
    [Abstract] [Full Text] [Related]

  • 12. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture.
    Arcamone F.
    Cancer Res; 1985 Dec; 45(12 Pt 1):5995-9. PubMed ID: 3864526
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
    Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg RM.
    Clin Cancer Res; 1998 Sep; 4(9):2111-7. PubMed ID: 9748127
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G, Spielmann M, Dieras V, Kayitalire L, Pouillart P, Guastalla JP, Soler-Michel P, Graffand N, Garet F, Dumortier A, Pellae-Cosset B, Chazard M.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [Abstract] [Full Text] [Related]

  • 19. Role of anthracyclines in the era of targeted therapy.
    Cortés-Funes H, Coronado C.
    Cardiovasc Toxicol; 2007 Feb; 7(2):56-60. PubMed ID: 17652804
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.